Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Description

The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery

Conditions

Intestinal Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery

Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Condition
Intestinal Disease
Intervention / Treatment

-

Contacts and Locations

Orange

UC Irvine Medical Center, Orange, California, United States, 92868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 or older
  • * Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission
  • * Allergy to Rocuronium, Vecuronium, or Sugammadex
  • * Bowel resection surgery requiring an ostomy
  • * No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
  • * No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
  • * Creatinine Clearance (CrCl) of less than 30
  • * Pregnancy
  • * Incapable of providing consent or understanding the research project

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Irvine,

Robert R Field, MD, PRINCIPAL_INVESTIGATOR, Associate Clinical Professor

Study Record Dates

2025-07-31